TY - JOUR
T1 - Characterization of proinsulin T cell epitopes restricted by type 1 diabetes-associated HLA Class II molecules
AU - Ihantola, Emmi Leena
AU - Ilmonen, Henna
AU - Kailaanmäki, Anssi
AU - Rytkönen-Nissinen, Marja
AU - Azam, Aurélien
AU - Maillère, Bernard
AU - Arlehamn, Cecilia S.Lindestam
AU - Sette, Alessandro
AU - Motwani, Keshav
AU - Seay, Howard R.
AU - Brusko, Todd M.
AU - Knip, Mikael
AU - Veijola, Riitta
AU - Toppari, Jorma
AU - Ilonen, Jorma
AU - Kinnunen, Tuure
N1 - Funding Information:
This work was supported by the Academy of Finland (Decision 307320), the Sigrid Jusélius Foundation, State Research Funding (VTR), and the Finnish Diabetes Research Foundation. The Finnish Type 1 Diabetes Prediction and Prevention study was supported by the Academy of Finland (Decisions 250114 and 286765), the Sigrid Jusélius Foundation, and the Juvenile Diabetes Research Foundation International (JDRF). The Network for Pancreatic Organ Donors with Diabetes is supported by the JDRF, with cooperative mechanistic study support by The Leona M. and Harry B. Helmsley Charitable Trust (to T.M.B.). The funders had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; and in the preparation, review, or approval of the manuscript.
Publisher Copyright:
© 2020 by The American Association of Immunologists, Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin-producing b cells within the pancreas are destroyed. Identification of target Ags and epitopes of the β cell-reactive T cells is important both for understanding T1D pathogenesis and for the rational development of Ag-specific immunotherapies for the disease. Several studies suggest that proinsulin is an early and integral target autoantigen in T1D. However, proinsulin epitopes recognized by human CD4+ T cells have not been comprehensively characterized. Using a dye dilution-based T cell cloning method, we generated and characterized 24 unique proinsulin-specific CD4+ T cell clones from the peripheral blood of 17 individuals who carry the high-risk DR3-DQ2 and/or DR4-DQ8 HLA class II haplotypes. Some of the clones recognized previously reported DR4-restricted epitopes within the C-peptide (C25-35) or A-chain (A1-15) of proinsulin. However, we also characterized DR3-restricted epitopes within both the Bchain (B16-27 and B22-C3) and C-peptide (C25-35). Moreover, we identified DQ2-restricted epitopes within the B-chain and several DQ2- or DQ8-restricted epitopes within the C-terminal region of C-peptide that partially overlap with previously reported DQ-restricted epitopes. Two of the DQ2-restricted epitopes, B18-26 and C22-33, were shown to be naturally processed from whole human proinsulin. Finally, we observed a higher frequency of CDR3 sequences matching the TCR sequences of the proinsulinspecific T cell clones in pancreatic lymph node samples compared with spleen samples. In conclusion, we confirmed several previously reported epitopes but also identified novel (to our knowledge) epitopes within proinsulin, which are presented by HLA class II molecules associated with T1D risk.
AB - Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin-producing b cells within the pancreas are destroyed. Identification of target Ags and epitopes of the β cell-reactive T cells is important both for understanding T1D pathogenesis and for the rational development of Ag-specific immunotherapies for the disease. Several studies suggest that proinsulin is an early and integral target autoantigen in T1D. However, proinsulin epitopes recognized by human CD4+ T cells have not been comprehensively characterized. Using a dye dilution-based T cell cloning method, we generated and characterized 24 unique proinsulin-specific CD4+ T cell clones from the peripheral blood of 17 individuals who carry the high-risk DR3-DQ2 and/or DR4-DQ8 HLA class II haplotypes. Some of the clones recognized previously reported DR4-restricted epitopes within the C-peptide (C25-35) or A-chain (A1-15) of proinsulin. However, we also characterized DR3-restricted epitopes within both the Bchain (B16-27 and B22-C3) and C-peptide (C25-35). Moreover, we identified DQ2-restricted epitopes within the B-chain and several DQ2- or DQ8-restricted epitopes within the C-terminal region of C-peptide that partially overlap with previously reported DQ-restricted epitopes. Two of the DQ2-restricted epitopes, B18-26 and C22-33, were shown to be naturally processed from whole human proinsulin. Finally, we observed a higher frequency of CDR3 sequences matching the TCR sequences of the proinsulinspecific T cell clones in pancreatic lymph node samples compared with spleen samples. In conclusion, we confirmed several previously reported epitopes but also identified novel (to our knowledge) epitopes within proinsulin, which are presented by HLA class II molecules associated with T1D risk.
U2 - 10.4049/jimmunol.1901079
DO - 10.4049/jimmunol.1901079
M3 - Article
AN - SCOPUS:85084048017
SN - 0022-1767
VL - 204
SP - 2349
EP - 2359
JO - Journal of immunology
JF - Journal of immunology
IS - 9
ER -